TrialNeurologia medico-chirurgica2017

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.

Tomokazu Aoki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.